For over 60 years delivering quality
Centroflora Group has spared no efforts in valuing Brazilian biodiversity as a source of Innovation for the Phytomedicines market.
With 64 years of history, Centroflora maintains its tradition as a manufacturer of botanical extracts, essential oils and isolated ingredients for the pharmaceutical industry. In recent years, it has also been consolidating itself as a national manufacturer of Active Pharmaceutical Ingredients (APIs), through new partnerships and investments to adapt its production and commercial structure.
Centroflora has technologies and processes that allow the isolation, extraction, concentration and drying of differentiated natural assets, with assured quality and traceability. As a result, it offers the market a wide variety of extracts from different regions of the planet, with special attention to those derived from Brazilian biodiversity, with total sustainability and respect for the environment; in other words, Centroflora has always acted in line with the principles that today are known as ESG.
Centroflora Group includes: (i) Anidro do Brasil; (ii) Phytobios, a company dedicated to radical and disruptive research and development, and (iii) Floravida Institute, a non-profit socio-environmental organization (NGO). In 2018, a joint venture called Brazbio has been created.
Foundation of Centroflora Group.
Opening of the Drying Plant, in Botucatu-SP.
Opening of the Botanic Extract Plant-SP.
Creation of Floravida Institute, a non-profit organization managed by the Group.
Acquisition of the Pharmochemical Plant in Paranaíba-PI and creation of the Partnerships for a Better World Program.
Acquisition of the agricultural area in Paranaíba-PI
Creation of the Jaborandi Valorization Program.
Opening of the Oil Extraction Plant in Parnaíba-PI.
Incorporation of 100% of the shares of Phytobios, until then a partner of Centroflora Group.
Creation of Centroflora CMS, a Joint Venture between Centroflora and CMS.
Incorporation of ASM Research Chemicals and L4P Foundation, specializing in pharmaceutical logistics.
Sale of the nutraceutical sector to Givaudan.
Completion of the CMS Joint Venture and creation of a distribution agreement between Centroflora and CMS (currently C²Pharma)
Creation of Brazbio, a Joint Venture between Givaudan and Centroflora, with shared management and focused on the development of sociobiodiversity production chains, continuing the work developed within the “Partnerships for a Better World Program”.
Centroflora IFA: delivery of a synthesis plant in Paranaíba-PI, with an investment of 18 million and a transfer project for the production of new APIs and prospecting for Cannabidiol production.
Opening of Centroflora Inova in Campinas (SP)
Opening of the Pilot Plant, of the new plant extract factory in Paranaíba (PI) and the beginning of the works of the new plant in Botucatu (SP).
Start of activities at the new plant in Botucatu (Spray Dryer)